Back

Long-term changes in primary prevention indication for ICD in patients with HFrEF

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Lifestyle, prevention and cardiac rehabilitation Implantable Cardioverter-Defibrillator (ICD) Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Zsuzsanna Majoros

Medical Centre- Hungarian Defence Forces, Budapest (Hungary)

6 More presentations in this session

Presentation thumbnail
Low-intensity exercise modulates skeletal muscle in a HFpEF animal model
Doctor L. Brochado (Almada, PT)
Abstract Slides Video
Presentation thumbnail
Physical activity and atrial phenotype: associations with echocardiography and P-wave indices in a population-based cohort
Doctor A. Zaghi (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Cardiac rehabiliation impact on VO2 recovery in heart failure - a post-hoc analysis of the EXIT-HF clinical trial
Doctor T. Peixoto (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Cardiac telerehabilitation improves physical function in frail older adults after acute decompensated heart failure: a randomised controlled trial (Tele-ADHF)
Miss M. Van Leunen (Veldhoven, NL)
Abstract Slides Video
Presentation thumbnail
Unrealized opportunities for heart failure prevention in CVD: ABC-HF risk stratification and outpatient target attainment
Doctor S. Azhgaliyeva (Aktobe, KZ)
Abstract Slides Video

Access the full session

Session thumbnail
Lifestyle, prevention and cardiac rehabilitation

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro
thumbnail
Congress Presentation
Limitations of current ICD indications in ischemic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources